Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2276 - 2300 of 14952 in total

Polythiazide

A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826)
Approved
Matched Description: … A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. …
Matched Categories: … polythiazide and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Pyridostigmine

Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and fatigue. Acetylcholinesterase inhibitors have been the symptomatic treatment of choice in myasthenia gravis since the 1930s with the...
Approved
Investigational
Matched Description: … under various brand and generic names. ... directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and ... By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and …

Ziconotide

Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail Conus magus comprising 25 amino acids with three disulphide bonds.[A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because...
Approved
Matched Iupac: … 3,6,9,12,15,22,25,28,31,34,37,40,43,46,49,52,55,58,61,70,73,76,79,84-tetracosaazatricyclo[40.37.4.2^{21,68}]pentaoctacontan-24-yl]acetic acid …
Matched Description: … [A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy …
Matched Categories: … Fluids and Secretions ... Calcium-Regulating Hormones and Agents …

Ciltacabtagene autoleucel

Multiple myeloma is a malignancy involving the plasma cells of the bone marrow. It is a rare malignancy, with an estimated yearly incidence of 6.5 people per 100,000, and is variable in its presentation - some patients may remain entirely asymptomatic, while others may experience a range of symptoms including...
Approved
Investigational
Matched Description: … It is a rare malignancy, with an estimated yearly incidence of 6.5 people per 100,000,[L40749] and is ... [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant ... asymptomatic, while others may experience a range of symptoms including bone pain, hematologic abnormalities, and …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Nadofaragene firadenovec

Nadofaragene firadenovec (nadofaragene firadenovec-vncg) is a recombinant non-replicating adenovirus serotype 5 vector containing a transgene encoding human interferon alfa-2b (IFNα2b). It was approved by the FDA on December 2022 for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without...
Approved
Investigational
Matched Description: … [L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat. ... firadenovec is formulated with an excipient (Syn-3) that facilitates gene transfer across the urothelium and …
Matched Categories: … Cellular and Gene Therapy ... Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Hexetidine

A bactericidal and fungicidal antiseptic. It is used as a 0.1% mouthwash for local infections and oral hygiene.
Approved
Investigational
Matched Description: … A bactericidal and fungicidal antiseptic. ... It is used as a 0.1% mouthwash for local infections and oral hygiene. …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... Antiinfectives and Antiseptics for Local Oral Treatment …

Rivastigmine

Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Approved
Investigational
Matched Description: … Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase …

Nitrofural

Nitrofural or nitrofurazone is a topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial wounds, burns, ulcers, and skin infections. Nitrofural has also been administered orally in the treatment of trypanosomiasis. Except for topical drug products formulated for dermatologic application, the FDA withdrew its approval...
Approved
Investigational
Vet approved
Withdrawn
Matched Description: … It is used for superficial wounds, burns, ulcers, and skin infections. ... Nitrofural or nitrofurazone is a topical anti-infective agent effective against gram-negative and gram-positive …
Matched Categories: … Antiseptics and Disinfectants ... Blood and Blood Forming Organs ... Blood Substitutes and Perfusion Solutions ... Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …

Fedratinib

Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
Approved
Investigational
Matched Description: … -2 and high risk primary and secondary myelofibrosis. ... Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Demecarium

Demecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it down. Demecarium inactivates both pseudocholinesterase...
Approved
Matched Description: … Demecarium inactivates both pseudocholinesterase and acetylcholinesterase. ... In the eye, this causes constriction of the iris sphincter muscle (causing miosis) and the ciliary muscle …
Matched Categories: … Antiglaucoma Preparations and Miotics …

Glofitamab

Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.[L45698,A258488] Glofitamab was approved...
Approved
Investigational
Matched Description: … It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting ... antigens found on B- and T-cells, respectively. ... Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Solifenacin

Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004.
Approved
Matched Description: … muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and …
Matched Categories: … tamsulosin and solifenacin ... Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …

Hexamidine

Approved
Experimental
Matched Categories: … Biguanides and Amidines ... Antiseptics and Disinfectants ... Ophthalmological and Otological Preparations …

Lifileucel

Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient which undergo isolation, ex vivo expansion, and activation Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma.
Approved
Investigational
Matched Description: … suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Medrogestone

Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective contraceptive option. It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing. It was never approved by the FDA.
Approved
Withdrawn
Matched Description: … [A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing …
Matched Categories: … medrogestone and estrogen ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Progestogens and Estrogens, Sequential Preparations …

Terizidone

Terizidone has been used in trials studying the treatment of Tuberculosis, HIV Infections, Multidrug Resistant Tuberculosis, and Extensively-drug Resistant Tuberculosis.
Approved
Investigational
Matched Description: … in trials studying the treatment of Tuberculosis, HIV Infections, Multidrug Resistant Tuberculosis, and …

Tremelimumab

Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours...
Approved
Investigational
Matched Description: … [A253717] By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces ... investigated in other cancers, such as colon cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Vosoritide

Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans. It results from a gain-of-function missense mutation in FGFR3 that results in a dramatic suppression of bone growth, both in volume and in length.[A242273,A242277] Treatment for achondroplasia includes both surgical and pharmacological interventions, the...
Approved
Investigational
Matched Description: … Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans ... missense mutation in _FGFR3_ that results in a dramatic suppression of bone growth, both in volume and ... [A242273,A242277] Treatment for achondroplasia includes both surgical and pharmacological interventions …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Lutetium Lu 177 dotatate

A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as...
Approved
Investigational
Matched Description: … Targeting pancreas and other parts of the gastrointestinal tract such as the intestines and colon, neuroendocrine ... tumors may commonly metastasize to metastasize to the mesentery, peritoneum, and liver [A31697]. ... The presence of a radioligand allows monitoring of treatment response post therapy and prior to next …
Matched Categories: … Indicators and Reagents ... Somatostatin and Analogues ... Amino Acids, Peptides, and Proteins …

Polistes annularis venom protein

Polistes annularis venom protein is an extract of Polistes annularis venom. Polistes annularis venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …

Olaratumab

Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the...
Approved
Investigational
Matched Description: … It is composed of two heavy chain molecule fragments and 2 light chain fragments. ... binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and ... olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Asfotase alfa

Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). Hypophosphatasia is almost always fatal when severe skeletal disease is obvious at birth. By replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels...
Approved
Investigational
Matched Description: … morbidity and premature death. ... Food and Drug Administration (FDA) on October 23, 2015. ... 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved by …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Teclistamab

Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells. Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide bonds,[A253587, L43622] allowing the drug...
Approved
Investigational
Matched Description: … is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and ... [A253587] Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Alglucerase

Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated...
Approved
Investigational
Withdrawn
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Racephedrine

Approved
Experimental
Matched Categories: … Herbs and Natural Products ... Alpha-and Beta-adrenergic Agonists …
Displaying drugs 2276 - 2300 of 14952 in total